These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27245604)

  • 1. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
    Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
    J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
    Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
    Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
    Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
    Kharlip J; Salvatori R; Yenokyan G; Wand GS
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
    Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
    J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary gland: can prolactinomas be cured medically?
    Molitch ME
    Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma.
    McCall D; Hunter SJ; Cooke RS; Herron B; Sheridan B; Atkinson AB
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):149-50. PubMed ID: 17201816
    [No Abstract]   [Full Text] [Related]  

  • 15. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
    Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
    Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
    Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.